Dated: July 26, 2024

To,

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Company Symbol: Dentalkart, ISIN: INE0N5801013

Subject: Outcome of the Meeting of the Board of Directors of VASA Denticity Limited (the Company") held on July 26, 2024

Respected Sir/ Madam,

Pursuant to the provisions of Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), we wish to inform you that the Board of Directors (the 'Board') of VASA Denticity Limited at their meeting held today i.e. Friday July 26, 2024, which commenced at 5:30 P.M. and concluded at 5:46 P.M. have inter alia:

- Approved Un-Audited Standalone and Consolidated Financial Results along with limited review reports received from the auditors of the Company for the quarter ended 30th June 2024.

Further, pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that the Statutory Auditors of the Company, **M/s KRA & Co.**, Chartered Accountants (FRN: 020266N), have expressed an Un-modified opinion in respect of Financial Results of the Company for the quarter ended on June 30, 2024.

Further, pursuant to Regulation 30(8) of the Listing Regulations the enclosed disclosures will be made available on the Company's website at: www.dentalkart.com.

You are requested to take the above information on your records please.

Thanking you,

For VASA Denticity Limited
(Formerly known as VASA Denticity Private Limited)

VIKAS AGARWAL
Digitally signed by VIKAS AGARWAL
Date: 2024.07.26 17:50:56 +05'30'

Vikas Agarwal
Managing Director
DIN: 07487686

Encl: a/a

K R A & CO.
Chartered Accountants
011 - 47082855
Fax: 011 - 47082855
H -1/208, Garg Tower, Netaji Subhash Place, Pitampura, New Delhi -110034

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Vasa Denticity Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ("the Statement") of **Vasa Denticity Limited** ('the Company') for the quarter ended June 30, 2024 ('the Statement'), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulation').
2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25") prescribed under section 133 of the Companies Act 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of Securities and Exchange Board of India (Listing and Disclosure Requirements) Regulations, 2015. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The standalone unaudited financial results include the results for the corresponding quarter ended June 30, 2023, which have been approved by the Company's Management but have not been subjected to audit or limited review. The result for the preceding quarter ended March 31, 2024, is the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figure up to the nine months ended December 31, 2023, of the previous financial year which is not subject to audit or limited review.

Our conclusion on the Statement is not modified in respect of the above matter

For KRA & Co.
Chartered Accountants
(Firm Registration No.020266N)



Saurabh
Partner
Membership No.: 510541
UDIN: 24510541BKAQAW2854
Place: New Delhi
Date: July 26, 2024

VASA DENTICITY LIMITED
(Formerly known as VASA DENTICITY PRIVATE LIMITED)
Regd. Office : KHASRA NO. 714, VILLAGE P.O. CHATTARPUR NEW DELHI SOUTH DELHI - 110074
CIN: U74999DL2016PLC305052
Website: www.dentalkart.com Email: cs@dentalkart.com Tel: 91-8527360456
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED JUNE 30, 2024

(Amount in Rs. Lacs)

Sl. No.	Particulars	Quarter Ended			Year Ended
		30.06.2024 (Unaudited)	31.03.2024 (Audited)	30.06.2023 (Unaudited)	31.03.2024 (Audited)
1	**Income**				
	a. Revenue from Operations	5,406.27	5,702.46	3,556.16	17,188.31
	b. Other Income	31.74	46.35	13.72	143.17
	Total Income	**5,438.01**	**5,748.81**	**3,569.88**	**17,331.48**
2	**Expenses**				
	a. Purchase of stock-in-trade	4,607.59	4,174.69	2,881.85	14,167.00
	b. Change in inventories of stock-in-trade	(463.24)	(60.16)	(246.34)	(1,618.56)
	c. Employee Benefits Expenses	279.54	212.51	215.27	883.09
	d. Finance Costs	0.05	0.61	3.24	7.29
	e. Depreciation and Amortisation Expenses	36.61	28.02	21.71	100.18
	f. Other Expenses	519.33	562.19	379.05	1,851.76
	Total Expenses	**4,979.88**	**4,917.86**	**3,254.78**	**15,390.76**
3	**Profit before exceptional and extraordinary items and tax**	**458.13**	**830.95**	**315.10**	**1,940.72**
4	Exceptional item	-	-	-	
5	**Profit before extraordinary items and tax**	**458.13**	**830.95**	**315.10**	**1,940.72**
6	Extraordinary items		-	-	
7	**Profit before tax**	**458.13**	**830.95**	**315.10**	**1,940.72**
8	**Tax expense**				
	a. Current Tax	122.61	188.64	65.75	428.16
	b. Deferred Tax	(6.41)	6.88	(5.41)	(9.63)
	c. Earlier year taxes	0.09	0.02	-	14.40
	Total tax expense	**116.29**	**195.54**	**60.34**	**432.93**
9	**Profit after tax**	**341.84**	**635.41**	**254.76**	**1,507.79**
10	**Paid-up Equity Share Capital (Face value of Rs.10 each)**	1,601.62	1,601.62	1,601.62	1,601.62
11	**Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year**	5,233.05	298.52	298.52	298.52
12	**Earnings Per Share (Face value of Rs. 10/- each)**				
	Basic (in Rs.) (not annualised)	2.13	3.97	1.84	9.73
	Diluted (in Rs.) (not annualised)	2.13	3.97	1.84	9.73

Notes:-

1 The above financial results for the quarter ended June 30, 2024 have been reviewed by Audit committee and approved by the Board of Directors in their respective meetings held on July 26, 2024.

2 The Company is engaged primarily in the business of trading dental products on PAN India basis. Accordingly, there are no separate reportable segments as per Accounting Standard 17 – "Segment Reporting".

3 The financial result has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard (AS) prescribed under section 133 of the Companies Act 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.

4 The figures for the corresponding quarter ended June 30, 2023 have been approved by the Company's Management, but have not been subjected to audit or review. The figures for the preceding quarter ended March 31, 2024 is the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figure up to the nine months ended December 31, 2023, of the previous financial year which is not subject to limited review or audit.

5 Figures for the previous year have been re-grouped/ rearranged/ restated wherever necessary to make them comparable with those of the current year.

Place: New Delhi
Date: 26.07.2024

For VASA DENTICITY LIMITED.



Vikas Agarwal
Managing Director
DIN -07487686

K R A & CO.
Chartered Accountants
011 - 47082855
Fax: 011 - 47082855
H -1/208, Garg Tower, Netaji Subhash Place, Pitampura, New Delhi -110034

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **Vasa Denticity Limited** ('the Holding Company') and its subsidiary (the Holding Company and its subsidiary constitute "the Group") for the quarter ended June 30, 2024 ('the Statement'), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulation').

2. This Statement which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25") prescribed under section 133 of the Companies Act 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of Securities and Exchange Board of India (Listing and Disclosure Requirements) Regulations, 2015. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of the following entity:

   i. Waldent Innovations Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results include the results for the preceding quarter ended March 31, 2024, which is the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figure up to the nine months ended December 31, 2023, of the previous financial year which is not subject to audit or limited review.

Our conclusion on the Statement is not modified in respect of the above matter

For KRA & Co.
Chartered Accountants
(Firm Registration No.020266N)



Saurabh
Partner
Membership No.: 510541
UDIN: 24510541BKAQAX2869
Place: New Delhi
Date: July 26, 2024

VASA DENTICITY LIMITED

(Formerly known as VASA DENTICITY PRIVATE LIMITED)

Regd. Office : KHASRA NO. 714, VILLAGE P.O. CHATTARPUR NEW DELHI SOUTH DELHI - 110074
CIN: U74999DL2016PLC305052
Website: www.dentalkart.com Email: cs@dentalkart.com Tel: 91-8527360456

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

(Amount in Rs. Lacs)

Sl. No.	Particulars	Quarter Ended		Year Ended
		30.06.2024	31.03.2024	31.03.2024
		(Unaudited)	(Audited)	(Audited)
1	**Income**			
	a. Revenue from Operations	5,406.27	5,702.46	17,188.31
	b. Other Income	31.74	46.38	143.20
	Total Income	**5,438.01**	**5,748.84**	**17,331.51**
2	**Expenses**			
	a. Purchase of stock-in-trade	4,607.59	4,174.69	14,167.00
	b. Change in inventories of stock-in-trade	(463.24)	(60.16)	(1,618.56)
	c. Employee Benefits Expenses	279.54	212.51	883.09
	d. Finance Costs	0.05	0.61	7.29
	e. Depreciation and Amortisation Expenses	36.61	28.14	100.42
	f. Other Expenses	520.61	562.12	1,851.69
	Total Expenses	**4,981.16**	**4,917.91**	**15,390.93**
3	**Profit before exceptional and extraordinary items and tax**	**456.85**	**830.93**	**1,940.58**
4	Exceptional item	-	-	
5	**Profit before extraordinary items and tax**	**456.85**	**830.93**	**1,940.58**
6	Extraordinary items		-	
7	**Profit before tax**	**456.85**	**830.93**	**1,940.58**
8	**Tax expense**			
	a. Current Tax	122.61	188.64	428.16
	b. Deferred Tax	(6.17)	6.95	(9.56)
	c. Earlier year taxes	0.09	0.02	14.40
	Total tax expense	**116.53**	**195.61**	**433.00**
9	**Profit after tax**	**340.32**	**635.32**	**1,507.58**
10	**Profit after tax attributable to:**			
	Owner of the Holding Company	340.32	635.32	1,507.58
	Minority Interest	-	-	-
11	**Paid-up Equity Share Capital (Face value of Rs.10 each)**	1,601.62	1,601.62	1,601.62
12	**Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year**	5,232.84	NA	NA
13	**Earnings Per Share (Face value of Rs. 10/- each)**			
	Basic (in Rs.) (not annualised)	2.12	3.97	9.72
	Diluted (in Rs.) (not annualised)	2.12	3.97	9.72

Notes:-

1 The above financial results for the quarter ended June 30, 2024 have been reviewed by Audit committee and approved by the Board of Directors in their respective meetings held on July 26, 2024.

2 The Group is engaged primarily in the business of trading dental products on PAN India basis. Accordingly, there are no separate reportable segments as per Accounting Standard 17 – "Segment Reporting".

3 The financial result has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard (AS) prescribed under section 133 of the Companies Act 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.

4 The figures for the preceding quarter ended March 31, 2024 is the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figure up to the nine months ended December 31, 2023, of the previous financial year which is not subject to limited review or audit.

5 The Holding Company acquired a subsidiary on 29.09.2023. Thus, there are no comparative figures for quarter ended 30.06.2023,

6 Figures for the previous year have been re-grouped/ rearranged/ restated wherever necessary to make them comparable with those of the current year.

Place: New Delhi
Date: 26.07.2024

For VASA DENTICITY LIMITED.



Vikas Agarwal
Managing Director
DIN -07487686